Announcements Trials
Browse Landscape

Phase

Phase 2/3 3Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 5Sleep Wake Disorders 1Sleep Disorders, Circadian Rhythm 1Radiodermatitis 1Radiation Injuries 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Keratosis, Actinic 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Depression 1Delirium 1Brain Neoplasms 1Brain Concussion 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Melatonin × Clear all
NCT02200172 2016-07-19

The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study

Bruyère Health Research Institute.

Phase 2 Completed
60 enrolled

Delirium, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡